ISIS Pharmaceuticals, Inc. Share Price Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 893.08Cr 778.78Cr 726.63Cr 668.15Cr 1.25TCr 85TCr 1.28TCr 8.61TCr 3.37TCr 42TCr 3.35TCr 3.28TCr 1,45900Cr | P/E 2026 * |
-16.8x | P/E 2027 * | -30.4x |
|---|---|---|---|---|---|
| Enterprise Value | 862.87Cr 752.43Cr 702.04Cr 645.54Cr 1.21TCr 83TCr 1.24TCr 8.32TCr 3.25TCr 41TCr 3.24TCr 3.17TCr 1,41000Cr | EV / Sales 2026 * |
8.8x | EV / Sales 2027 * | 6.22x |
| Free-Float |
99.08% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 01/07/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 01/01/2020 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 01/05/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 13/12/2005 |
| Director/Board Member | 73 | 01/05/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 25/03/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 914.23Cr | |
| +2.61% | +1.91% | +1.70% | +13.91% | 4.79TCr | |
| -1.60% | -1.29% | +385.56% | +603.70% | 3.91TCr | |
| -0.98% | +2.68% | +11.10% | +45.34% | 3.67TCr | |
| +1.90% | +22.79% | +25.18% | +9.47% | 4.05TCr | |
| +1.47% | +4.90% | +6.48% | +43.52% | 2.8TCr | |
| -0.94% | -1.23% | - | - | 1.68TCr | |
| +2.44% | +10.02% | +29.11% | +129.56% | 1.59TCr | |
| +0.18% | -1.46% | +4.92% | +10.14% | 1.36TCr | |
| -1.14% | +6.94% | -6.05% | -29.33% | 1.38TCr | |
| Average | +0.53% | +4.66% | +57.25% | +103.29% | 2.8TCr | |
| Weighted average by Cap. | +0.64% | +5.06% | +73.07% | +124.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 98Cr 86Cr 80Cr 73Cr 137.73Cr 9.38TCr 141.02Cr 946.15Cr 369.83Cr 4.65TCr 368.3Cr 360.31Cr 16TCr | 139.67Cr 121.79Cr 113.64Cr 104.49Cr 196.09Cr 13TCr 200.78Cr 1.35TCr 526.53Cr 6.62TCr 524.35Cr 512.98Cr 23TCr |
| Net income | -53Cr -46Cr -43Cr -40Cr -75Cr -5.08TCr -76Cr -511.85Cr -200.07Cr -2.52TCr -199.24Cr -194.92Cr -8.67TCr | -28Cr -25Cr -23Cr -21Cr -40Cr -2.72TCr -41Cr -274.48Cr -107.29Cr -1.35TCr -106.84Cr -104.53Cr -4.65TCr |
| Net Debt | -30Cr -26Cr -25Cr -23Cr -42Cr -2.89TCr -43Cr -291.4Cr -113.9Cr -1.43TCr -113.43Cr -110.97Cr -4.94TCr | -24Cr -21Cr -20Cr -18Cr -34Cr -2.3TCr -34Cr -231.46Cr -90Cr -1.14TCr -90Cr -88Cr -3.92TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
